Patients with medulloblastomas after primary therapy have a particularly poor prognosis, with a median survival of less than 6 months;the 2-year survival rate of approximately 9%. Th17 cells (a new member of the CD4+ ...
详细信息
Patients with medulloblastomas after primary therapy have a particularly poor prognosis, with a median survival of less than 6 months;the 2-year survival rate of approximately 9%. Th17 cells (a new member of the CD4+ effector T-cell family) have substantially advanced our understanding of T cell-mediated immunity. The aim of this study was to investigate the role of T (Treg) and Th17 cells in medulloblastom immune pathology and therapy.
暂无评论